Releases Details

Holding(s) in Company

Feb 22, 2022
RNS Number : 4691C
MaxCyte, Inc.
22 February 2022
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

US57777K1060

Issuer Name 

MAXCYTE, INC. 

UK or Non-UK Issuer

Non-UK 

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name 

Vitruvian Partners LLP 

City of registered office (if applicable)

London 

Country of registered office (if applicable)

United Kingdom 

4. Details of the shareholder

Name 

City of registered office

Country of registered office

Life Tech S.à r.l.

Luxembourg

Luxembourg

5. Date on which the threshold was crossed or reached

17-Feb-2022 

6. Date on which Issuer notified

21-Feb-2022 

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

4.010000

0.000000

4.010000

4053531

Position of previous notification (if applicable)

3.110000

0.000000

3.110000


8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

US57777K1060

4053531

0

4.010000

0.000000

Sub Total 8.A

4053531

4.010000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights






Sub Total 8.B1




8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights







Sub Total 8.B2




9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold






10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

- The Vitruvian Investment Partnership III is managed by Vitruvian Partners LLP and is deemed to be the ultimate beneficial owner of Life Tech S.à r.l.
- The voting rights attached to shares disclosed herein - 4,053,531, equivalent to 4.01% of issuer's voting rights - are comprised by 2,430,000 LSE (AIM) listed shares (LSE SEDOL: BYVJZ42) and by 1,623,531 US NASDAQ listed shares (NASDAQ: SEDOL BKMQF66).

12. Date of Completion

21-Feb-2022 

13. Place Of Completion

London 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFEEFFIFFIF